Implications of early COVID-19 vaccine data

News this week has largely been dominated by talk about a COVID-19 vaccine and finnCap’s Rude Health Life Sciences Sector Report is one of the first to focus on the implications of the early data surrounding the vaccine. The report acknowledges that the initial results are promising but warns that an over-reaction in the market shouldn’t diminish the need for more treatments and testing in the future. At the beginning of the week, Pfizer and BioNTech announced the first interim analysis from the Phase III study of its COVID-19 vaccine candidate, which was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.